NCT02842749 2025-02-10
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Novartis
Phase 4 Completed
Clinical Trials
36 trialsNCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT01642186 2022-12-29
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00981162 2022-09-13
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Roswell Park Cancer Institute
Phase 1 Completed
NCT01154335 2022-05-03
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT01077986 2021-04-21
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT00560963 2020-12-21
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
Novartis
Phase 1/2 Completed
NCT01248403 2020-01-29
AIO-STO-0111
Krankenhaus Nordwest
Phase 3 Completed
NCT00729482 2020-01-07
RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
Asan Medical Center
Phase 2 Completed
NCT01049620 2020-01-07
RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX
Asan Medical Center
Phase 1 Completed
NCT01005199 2019-05-15
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT00419159 2019-04-23
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Novartis
Phase 2 Completed
NCT01514110 2019-04-02
Gastric Cancer RAD001 Study
Chinese University of Hong Kong
Phase 1/2 Completed
NCT02305810 2018-11-07
A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
European Institute of Oncology
Phase 2 Completed
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT01567488 2018-01-03
EVERLAR
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT00955773 2017-11-09
Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01139138 2017-11-06
PIE
The Queen Elizabeth Hospital
Phase 1/2 Completed
NCT01058655 2017-04-13
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01047293 2017-04-04
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
University of Utah
Phase 1/2 Completed
NCT00516165 2017-02-07
RAD001 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 1/2 Completed
NCT00949949 2017-01-12
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Mayo Clinic
Phase 1 Completed
NCT00519324 2016-11-18
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
Novartis
Phase 2 Completed
NCT01035229 2016-09-22
EVOLVE-1
Novartis
Phase 3 Completed
NCT01099527 2015-12-29
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
Samsung Medical Center
Phase 1/2 Completed
NCT00879333 2015-11-03
GRANITE-1
Novartis
Phase 3 Completed
NCT00522665 2015-05-15
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT00409292 2014-08-11
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00632268 2013-08-21
Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer
National Taiwan University Hospital
Phase 2 Completed
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed
NCT00478634 2012-11-02
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Novartis
Phase 1 Completed
NCT01042782 2012-08-03
S387
Krankenhaus Nordwest
Phase 1 Completed
NCT00775073 2012-04-30
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Treiber, Gerhard
Phase 2 Completed
NCT01387880 2012-03-20
ICE
Herlev Hospital
Phase 2 Completed